Efficacy of Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.

Trial Profile

Efficacy of Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs Rosuvastatin/valsartan (Primary) ; Rosuvastatin; Valsartan
  • Indications Dyslipidaemias; Hypertension
  • Focus Therapeutic Use
  • Sponsors EMS
  • Most Recent Events

    • 25 Jan 2017 Timeframe for primary endpoint has been changed from 4 weeks to 8 weeks. Also treatments arms has been changed from 2 to 4
    • 25 Jan 2017 Planned number of patients changed from 334 to 632.
    • 25 Jan 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top